Bank of America sees 'attractive entry point' in Kenvue after Tylenol controversy sparks sell-off

Bank of America has reiterated its Buy rating and $25 price target for Kenvue (KVUE), viewing the stock's recent 10%+ sell-off as an attractive buying opportunity. This downturn followed a report suggesting the HHS may link Tylenol to autism, but analyst Anna Lizzul dismisses the material impact of this risk, citing prior FDA findings that found no causal link. BofA remains bullish on Kenvue's fundamentals, noting its discount to peers and achievable 2025 guidance, projecting over 34% potential upside.

Analysis

Bank of America is reiterating its Buy rating on Kenvue (KVUE), framing the stock's recent sell-off as an attractive entry point for investors. The share price slid more than 10% following a report that the U.S. Department of Health and Human Services (HHS) may link Tylenol to autism. However, BofA analyst Anna Lizzul views this as a non-material risk, highlighting that the FDA in 2023 could not support a causal link and that a litigation expert believes establishing direct causation without new scientific evidence is unlikely. The core of the bullish thesis is valuation-driven; Kenvue is currently trading at a discount to peers like Procter & Gamble on an 11x CY26e EV/EBITDA multiple. BofA applies a 13x multiple to derive its $25 price target, which implies over 34% potential upside. This outlook is further supported by confidence in Kenvue's new management team, which has reset expectations with a 2025 guidance that BofA deems achievable, despite forecasting improving but still negative organic sales through 2025.

Key Decisions for Investors

• Investors may consider the recent share price weakness, which has pushed the stock down 12.8% year-to-date, as a buying opportunity based on the analyst's view that the valuation is attractive and the litigation risk is contained.
• It is critical to monitor the impending HHS report and any subsequent legal or regulatory developments, as any new, credible scientific evidence establishing a Tylenol-autism link would invalidate the analyst's core risk assessment.
• Investors should scrutinize Kenvue's upcoming earnings reports for evidence of execution by the new leadership, particularly focusing on organic sales trends to confirm they are on track to meet the 'achievable' but lowered 2025 guidance.